Myfxtools
  • Login
  • Expert Advisors
  • Forex Signals
    • Best Forex Signals
  • Forex Brokers
  • Forex Trading
    • Forex Guides
    • Analytical Tools
    • Charting Software
  • Crypto Trading
  • Portfolios
No Result
View All Result
  • Expert Advisors
  • Forex Signals
    • Best Forex Signals
  • Forex Brokers
  • Forex Trading
    • Forex Guides
    • Analytical Tools
    • Charting Software
  • Crypto Trading
  • Portfolios
  • Login
Myfxtools
Home News

Celldex Therapeutics Trial Success

by Myfxtools
February 26, 2024
in News
Share on TwitterShare on Facebook

Positive Outcome for Chronic Spontaneous Urticaria Treatment

Shares of Celldex Therapeutics experienced a 17% increase, reaching $44.35, following the successful trial of a treatment for chronic spontaneous urticaria.

The New Jersey-based company announced that its Phase 2 trial of barzolvolimab in treating CSU had met its primary efficacy endpoint, showing a significant change in urticaria activity score compared to the placebo after 12 weeks.

Plans for Phase 3 Program Initiation

With this promising outcome, Celldex is now in the process of actively preparing for the launch of its Phase 3 program in CSU this summer. CEO Anthony Marucci expressed optimism about the future of the treatment.

Strong Financial Performance

In addition to the positive trial results, the company also reported impressive fourth-quarter financial results. Revenue increased to $4.1 million from $1.6 million, surpassing analysts’ expectations of $900,000.

The boost in revenue was attributed to expanded services provided under manufacturing and research and development agreements with Rockefeller University.

Secure Financial Position

Celldex stated that it expects its current cash reserves and marketable securities to support operations through 2026, providing a solid foundation for future development and growth.

forex ea chart
Would you like to try out trading with an Expert Advisor?
Check Out Best Forex EAs Here
Tags: Celldex Therapeuticsclinical trialsCSU TreatmentPhase 3 Programstock market
Previous Post

Bank of Ireland Forecasts Income Shifts

Next Post

Croda International 2023 Results Preview

Next Post

Croda International 2023 Results Preview

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

37 − = 31

Recent Posts

  • Dividend Funds See Resurgence Amid Rate-Cut Bets, Volatility
  • Fed Stress Tests Clear All Banks Amid Softer Scenarios
  • U.S. Stocks Close Out Second Strong Month with Gains
  • U.S. Court Orders Argentina to Cede YPF Stake
  • Economic Calendar for the Week of June 29th
  • About Us
  • Contact Us
  • Privacy Policy
  • Risk Disclosure
Myfxtools turns raw trade logs into verified dashboards and AI-driven insights - helping traders see, share, and sharpen their edge.

© 2025, Myfxtools. All rights reserved.

AI Strategy Insight is educational and not financial advice.

  • Expert Advisors
  • Forex Signals
    • Best Forex Signals
  • Forex Brokers
  • Forex Trading
    • Forex Guides
    • Analytical Tools
    • Charting Software
  • Crypto Trading
  • Portfolios

© 2025, Myfxtools. All rights reserved.

AI Strategy Insight is educational and not financial advice.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In